TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33731199
Drug: First-line platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line platinum-based double chemotherapy regimens
Study: 33518358
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (smoking cessation counseling and nicotine lozenges)
Study: 34995105
Drug: Palbociclib with
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib with adjuvant endocrine therapy (ET) for 2 years
Study: 34995105
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine therapy (ET) alone
Study: 34680134
Drug: Molecular iodine
Normalized name: molecular iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular iodine (I2) supplementation (5 mg/day)
Study: 34680134
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with molecular iodine (Cht+I2)
Study: 34954044
Drug: Tucatinib combination
Normalized name: tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tucatinib combination (tucatinib + trastuzumab + capecitabine)
Study: 34954044
Drug: Placebo combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combination (placebo + trastuzumab + capecitabine)
Study: 33205906
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methotrexate plus etanercept)
Study: 33205906
Drug: Rescue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy (combination regimen)
Study: 37810589
Drug: Aflibercept 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2.0 mg
Study: 34550375
Drug: Low birth
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low birth weight (LBW; <2500 g)
Study: 33884713
Drug: Extra virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra virgin olive oil (EVOO), 25 mL/day for 52 days
Study: 33884713
Drug: Sunflower oil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil, 25 mL/day for 52 days
Study: 34767896
Drug: PIZ >
Normalized name: Pizotifen
DrugBank: Pizotifen (DB06153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIZ > median (>14 ml)
Study: 32057574
Drug: Standard Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose (SD) - 2 standard doses on weeks 0 and 4
Study: 32057574
Drug: Double Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double Dose (DD) - 2 double-standard doses on weeks 0 and 4
Study: 32057574
Drug: Booster Dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster Dose (BD) - 3 standard doses on weeks 0, 4, and 12
Study: 34767030
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow aspirate concentrate (BMAC) injection
Study: 33358336
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 μg kg−1 h−1) with propofol infusion
Study: 33358336
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 0.9%) with propofol infusion
Study: 32935997
Drug: Molecular-targeted treatments
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular-targeted treatments
Study: 34689304
Drug: New galenics
Approvals — FDA: no, EMA: no, PMDA: no
Description: New galenics nasal spray (nasic® neo)
Study: 34689304
Drug: Comparator nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator nasal spray
Study: 34689304
Drug: New galenics
Approvals — FDA: no, EMA: no, PMDA: no
Description: New galenics nasal spray (nasic® neo) in subgroup with pronounced inflammation
Study: 32907366
Drug: BMS-986141 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986141 (400 ng/mL)
Study: 32907366
Drug: BMS-968141 (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-968141 (combined with low-dose apixaban)
Study: 32907366
Drug: Apixaban (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (low-dose 20 ng/mL)
Study: 36415003
Drug: Dual task
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual task (DT) training for three weekly sessions for 8 weeks, 60 min each
Study: 36183051
Drug: Socio-Cognitive Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socio-Cognitive Behavioral Therapy for Suicidal Behaviors (SCBT-SB)
Study: 33269798
Drug: Sinovac EV71
Normalized name: COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinovac EV71 vaccine (Older-S group)
Study: 33269798
Drug: Control EV71
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control EV71 vaccine (Older-C group)
Study: 33269798
Drug: Sinovac EV71
Normalized name: COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinovac EV71 vaccine (Younger-S group)
Study: 32449542
Drug: Stimulation off/medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation off/medication on condition
Study: 33360684
Drug: Lys-FFA (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lys-FFA (500 mg EPA plus 302 mg DHA)
Study: 33360684
Drug: EE (504
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE (504 mg EPA plus 378 mg DHA)
Study: 33905630
Drug: OneTouch Reveal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OneTouch Reveal app (used for 12 weeks) in Subgroup C (fixed insulin dose)
Study: 33905630
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group A, treated with continuous subcutaneous insulin infusion (CSII))
Study: 33078435
Drug: Daily aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily aerobic cycling exercise (35 min at 60% VO2max)
Study: 32503602
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (0.1 ml of the licensed BCG vaccine, Danish strain 1331, SSI, Denmark, equivalent to 0.075 mg attenuated M. bovis)
Study: 32503602
Drug: Placebo (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.1 ml 0.9% NaCl)
Study: 35038432
Drug: Sugemalimab plus
Normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab plus platinum-based chemotherapy (1200 mg intravenously every 3 weeks)
Study: 38101431
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus platinum-based chemotherapy
Study: 35038432
Drug: Sugemalimab plus
Normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab plus chemotherapy
Study: 36498288
Drug: Therapy using
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy using PNF, NDT-Bobath methods and the SPIDER system
Study: 36498288
Drug: Therapy using
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy using PNF and NDT-Bobath methods, without the SPIDER system
Study: 36149770
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (VITC; ∼2‐3 g)
Study: 36149770
Drug: Oral BH4
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral BH4 (KUVAN, 10 mg/kg body wt)
Study: 33517804
Drug: L-Carnitine (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine (3000 mg daily until ovulation)
Study: 32874108
Drug: Jump training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jump training (twice-weekly for 8 weeks)
Study: 36263002
Drug: Remimazolam besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam besylate (RB) combined with alfentanil (10 μg/Kg alfentanil + RB 0.2 mg/kg intravenously)
Study: 36263002
Drug: Propofol combined
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol combined with alfentanil (10 μg/Kg alfentanil + propofol 1.5 mg/kg)
Study: 34246485
Drug: Tegoprazan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan (200 mg) under fasting condition
Study: 34246485
Drug: Tegoprazan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan (200 mg) under fed condition
Study: 33229756
Drug: Recombinant EPO
Normalized name: EPOETIN ALFA,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant EPO Beta (Recormon) administered via subcutaneous route in weekly doses of 2000 IU, 4000 IU, 6000 IU, 8000 IU, 12,000 IU, or 18,000 IU according to the severity of anemia.
Study: 32660811
Drug: Therapeutic recommendation
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic recommendation for treatment of abnormal infant heads based on perceived deformity severity.
Study: 35253334
Drug: Pioglitazone <15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone <15 mg/day
Study: 35253334
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg/day and 30 mg/day (pooled)
Study: 35253334
Drug: Pioglitazone <45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone <45 mg/day
Study: 35253334
Drug: Pioglitazone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (all doses)
Study: 33986479
Drug: NSAID pre-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAID pre-operative administration (Ibuprofen)
Study: 32812384
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil group (EPA-rich fish oil: 600 mg EPA and 260 mg DHA per day for 8 weeks)
Study: 32812384
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (matching capsules for the same duration)
Study: 34786904
Drug: Intrauterine G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine G-CSF injections
Study: 34786904
Drug: Intrauterine hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine hCG injections (500 IU)
Study: 34786904
Drug: Intrauterine saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine saline solution (placebo)
Study: 35580701
Drug: Ketamine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (target plasma concentration 100 ng/mL)
Study: 33235184
Drug: Leflunomide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (20 mg/day for 3 months)
Study: 33235184
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of leflunomide and everolimus
Study: 36056369
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam before the operation
Study: 36056369
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo before the operation
Study: 32816830
Drug: Fibre-fix supplement
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre-fix supplement added to a low FODMAP diet
Study: 33999741
Drug: Opioid Treatment
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid Treatment Programs (OTP) in inpatient treatment
Study: 33999741
Drug: Opioid Treatment
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid Treatment Programs (OTP)
Study: 33710353
Drug: No skin
Normalized name: Aveeno Skin Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: No skin treatment before surgery (Control)
Study: 35460853
Drug: Type of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type of anesthesia administered
Study: 34231532
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment for severe ROP
Study: 34231532
Drug: Anti-VEGF treatment
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF treatment (bevacizumab) for severe ROP
Study: 34231532
Drug: Anti-VEGF treatment
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF treatment (bevacizumab)
Study: 32312727
Drug: Hydrosurgical debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrosurgical debridement ± decellularised dermal allograft, or combination with negative pressure wound therapy, as an adjunct to treatment as usual (TAU)
Study: 32312727
Drug: One treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One treatment strategy continued from phase II
Study: 34488853
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted Cognitive Behavioural Therapy (CaCBT)
Study: 34488853
Drug: Standard Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Cognitive Behavioural Therapy (CBT)
Study: 32460790
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg GBS
Study: 32460790
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg GBS
Study: 33966113
Drug: Mesotherapy (intra‐mucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesotherapy (intra‐mucosal injection of ascorbic acid, 1/week for 3 weeks)
Study: 33966113
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel (topical ascorbic acid gel, 1/day for 3 months)
Study: 35288066
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg) every 2 weeks for ≤1 year
Study: 34544599
Drug: Px563L (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Px563L (10 mcg)
Study: 34544599
Drug: Px563L (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Px563L (50 mcg)
Study: 34544599
Drug: Px563L (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Px563L (80 mcg)
Study: 34544599
Drug: Px563L (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Px563L (all doses)
Study: 35696185
Drug: Semorinemab 1500
Normalized name: Semorinemab
DrugBank: Semorinemab (DB15234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semorinemab 1500 mg
Study: 35696185
Drug: Semorinemab 4500
Normalized name: Semorinemab
DrugBank: Semorinemab (DB15234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semorinemab 4500 mg
Study: 35696185
Drug: Semorinemab 8100
Normalized name: Semorinemab
DrugBank: Semorinemab (DB15234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semorinemab 8100 mg
Study: 34401684
Drug: Exteroceptive control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exteroceptive control therapy (emotional prosody identification)
Study: 32957364
Drug: Heat-sensitive moxibustion
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-sensitive moxibustion self-administration + original antihypertensive drugs
Study: 32957364
Drug: Original antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original antihypertensive drugs without heat-sensitive moxibustion
Study: 35583232
Drug: High-dose clazakizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clazakizumab (25 mg)
Study: 33529093
Drug: Inactivated monovalent
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated monovalent EV-71 vaccine
Study: 33093359
Drug: Non-aspirin
Normalized name: Non-Aspirin
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin
Study: 32352811
Drug: Mindfulness practice
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness practice (daily diary assessments)
Study: 35533197
Drug: Glutamate infusion
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate infusion (0.125 M L-glutamic acid at 1.65 mL/kg/h)
Study: 35533197
Drug: Glutamate infusion
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate infusion (in patients without diabetes)
Study: 33115436
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blocker (ARB) treatment with irbesartan (150–300 mg)
Study: 33413459
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg) in the morning
Study: 33413459
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg) in the afternoon
Study: 36088445
Drug: PolyPrime intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: PolyPrime intervention (online video and medication reviews scheduled twice)
Study: 32838783
Drug: Family-administered screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-administered screening with a 6.9 cm card for assessing baby's foot size.
Study: 35098601
Drug: Fitness app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fitness app and activity tracker (treatment group)
Study: 34209273
Drug: Alcoholic beer
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic beer (AB) - 330 mL/day
Study: 34209273
Drug: Non-alcoholic beer
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-alcoholic beer (NAB) - 660 mL/day
Study: 34115953
Drug: L-DGG (Er,Cr:YSGG-harvested
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DGG (Er,Cr:YSGG-harvested DGG and root surface biomodified)
Study: 35848935
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) group intervention, 14 sessions of 2 hours each
Study: 33077119
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg ⋅ kg‐1)
Study: 35261292
Drug: Warm saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm saline solution for postoperative care
Study: 35918657
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of vancomycin
Study: 35918657
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion (II) of vancomycin
Study: 35442543
Drug: Atopalm cream®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopalm cream® (twice-daily application for three consecutive years)
Study: 32967742
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of oral powder-based chocolate-flavoured CGMP for 4 weeks
Study: 33012641
Drug: 50% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% dose reduction of IAsp (2.6 ± 1.2 IU) before and after exercise
Study: 33012641
Drug: 50% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% dose reduction of IAsp post-exercise
Study: 33012641
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 50% dose reduction of IAsp before and after exercise
Study: 33012641
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose of IAsp (100%; 5.1 ± 2.4 IU)
Study: 33830440
Drug: PEG 3350
Normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 3350 (0.7–1.5 mg/kg/day)
Study: 33830440
Drug: Lactulose (0.7–2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (0.7–2.0 g/kg/day)
Study: 33208855
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) treatment for menopausal hot flushes, twice a day for four weeks
Study: 34412521
Drug: empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin 25 mg/d (n = 43)
Study: 35513301
Drug: 2-g cephazolin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g cephazolin
Study: 35513301
Drug: Placebo (10-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10-mL normal saline)
Study: 35869554
Drug: modified Xiao-Feng
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified Xiao-Feng Powder (mXFP) with antihistamine Bilastine
Study: 35869554
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with antihistamine Bilastine
Study: 32891418
Drug: Pitavastatin/Fenofibrate combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin/Fenofibrate combination therapy (2/160 mg)
Study: 32891418
Drug: Pitavastatin monotherapy
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin monotherapy (2 mg)
Study: 33153482
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care psychosocial intervention (17-week program delivered at home by community health workers with tablet application)
Study: 32492293
Drug: Hydroxychloroquine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days)
Study: 35392739
Drug: Galcanezumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab (240 mg loading dose, then 120 mg/month thereafter)
Study: 32681228
Drug: Antibiotics/Hydroxychloroquine (ciprofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics/Hydroxychloroquine (ciprofloxacin 500 mg bd, doxycycline 100 mg bd, hydroxychloroquine 200 mg tds for 4 weeks, followed by doxycycline 100 mg bd and hydroxychloroquine 200 mg tds for 20 weeks)
Study: 32681228
Drug: Budesonide (Entocort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (Entocort CR 9 mg/day for 8 weeks, 6 mg/day for 2 weeks, 3 mg/day for 2 weeks)
Study: 32681228
Drug: Antibiotics/Hydroxychloroquine (including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics/Hydroxychloroquine (including crossover)
Study: 32472292
Drug: Taurine 3000
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine 3000 mg/daily for 8 weeks
Study: 32472292
Drug: Placebo (crystalline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (crystalline microcellulose/daily for 8 weeks)
Study: 35545412
Drug: Dexmedetomidine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.3 μg/(kg·h) (Dex1 group)